+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236



No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236



International Journal of Radiation Oncology, Biology, Physics 88(5): 1092-1099



To investigate pulmonary function test (PFT) results and arterial blood gas changes (complete PFT) following stereotactic body radiation therapy (SBRT) and to see whether baseline PFT correlates with lung toxicity and overall survival in medically inoperable patients receiving SBRT for early stage, peripheral, non-small cell lung cancer (NSCLC). During the 2-year follow-up, PFT data were collected for patients with T1-T2N0M0 peripheral NSCLC who received effectively 18 Gy × 3 in a phase 2 North American multicenter study (Radiation Therapy Oncology Group [RTOG] protocol 0236). Pulmonary toxicity was graded by using the RTOG SBRT pulmonary toxicity scale. Paired Wilcoxon signed rank test, logistic regression model, and Kaplan-Meier method were used for statistical analysis. At 2 years, mean percentage predicted forced expiratory volume in the first second and diffusing capacity for carbon monoxide declines were 5.8% and 6.3%, respectively, with minimal changes in arterial blood gases and no significant decline in oxygen saturation. Baseline PFT was not predictive of any pulmonary toxicity following SBRT. Whole-lung V5 (the percentage of normal lung tissue receiving 5 Gy), V10, V20, and mean dose to the whole lung were almost identical between patients who developed pneumonitis and patients who were pneumonitis-free. Poor baseline PFT did not predict decreased overall survival. Patients with poor baseline PFT as the reason for medical inoperability had higher median and overall survival rates than patients with normal baseline PFT values but with cardiac morbidity. Poor baseline PFT did not appear to predict pulmonary toxicity or decreased overall survival after SBRT in this medically inoperable population. Poor baseline PFT alone should not be used to exclude patients with early stage lung cancer from treatment with SBRT.

(PDF emailed within 0-6 h: $19.90)

Accession: 054629864

Download citation: RISBibTeXText

PMID: 24661663

DOI: 10.1016/j.ijrobp.2013.12.050


Related references

Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 73(4): 1235-1242, 2009

Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 85(4): 1074-1081, 2013

Low Lung Density In Patients With Pulmonary Emphysema Increases The Risk Of Local Failure For Peripheral Early-stage Non-small Cell Lung Cancer (NSCLC) Treated With Stereotactic Body Radiation Therapy (SBRT). International Journal of Radiation Oncology*biology*physics 81(2): S586-S587, 2011

Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes. Journal of Radiosurgery and Sbrt 2(4): 333-338, 2018

Stereotactic body radiation therapy (SBRT) for early stage lung cancer delivers clinically significant radiation to the draining lymph nodes. Journal of Radiosurgery and Sbrt 2(4): 339-340, 2014

A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). International Journal of Radiation Oncology, Biology, Physics 93(4): 757-764, 2016

Comparison of Single- and Five-fraction Regimens of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-small-cell Lung Cancer: A Two-institution Propensity-matched Analysis. Clinical Lung Cancer 19(6): 511-517, 2018

Comparison of Single- and Three-fraction Schedules of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-Small-cell Lung Cancer. Clinical Lung Cancer 19(2): E235-E240, 2017

Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 2018, 2018

Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics 101(3): 558-563, 2018

Survival Outcome after Stereotactic Body Radiation Therapy and Surgery for Early Stage Non-Small Cell Lung Cancer: A Meta-Analysis. Journal of Investigative Surgery 2017: 1-8, 2017

Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer in Patients 80 Years and Older: A Multi-Center Analysis. International Journal of Radiation Oncology, Biology, Physics 98(1): 229-230, 2017

Radiation pneumonitis after stereotactic body radiation therapy for early stage non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 17(4): 351-356, 2015

Stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Expert Review of Anticancer Therapy 8(1): 87-98, 2007

Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncology 4(9): 1263-1266, 2018